Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial
- Journal:
- Nature Communications
- Published:
- Affiliations:
- 4
- Authors:
- 18
| Institutions | Authors | Share |
|---|---|---|
| Sun Yat-sen University Cancer Center (SYSUCC), SYSU, China | 0.89 | |
| Huizhou Municipal Central Hospital, China | 0.06 | |
| The Second Hospital of Dalian Medical University, China | 0.06 |